Rigel Pharmaceuticals, Inc. (RIGL)
44.11
+0.71
(+1.64%)
USD |
NASDAQ |
Dec 09, 10:48
Rigel Pharmaceuticals EPS Diluted (Quarterly): 1.456 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Eli Lilly & Co. | 6.211 |
| Catalyst Pharmaceuticals, Inc. | 0.4153 |
| Amicus Therapeutics, Inc. | 0.0558 |
| Perspective Therapeutics, Inc. | -0.3495 |
| Nektar Therapeutics | -1.875 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 27.90M |
| Revenue (Quarterly) | 69.46M |
| Total Expenses (Quarterly) | 41.56M |
| Enterprise Value | 711.50M |
| Gross Profit Margin (Quarterly) | 93.16% |
| Profit Margin (Quarterly) | 40.17% |
| Earnings Yield | 13.98% |
| Operating Earnings Yield | 14.68% |
| Normalized Earnings Yield | 13.98 |